Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2018
SIETES contiene 92588 citas

 
 
 1 a 7 de 7 
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Baah JO, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li P-Z, Hill PC, Schwartzman K, Benedetti A, Menzies D. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102756]
2.Tiene citas relacionadas Cita con resumen
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Baah JO, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata KE, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion-M-J, Li P-Z, Schwartzman K, Benedetti A. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102755]
3. Cita con resumen
Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med 2016;176:55-63. [Ref.ID 99990]
4. Cita con resumen
Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med 2014;174:890-8. [Ref.ID 97660]
5.Tiene citas relacionadas Cita con resumen
Equale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 2012;172:781-8. [Ref.ID 93053]
6.Enlace a cita original
Ahuja SD, Ashkin D, Avendaño M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang C-Y, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman M, Jarlsberg LG, Keshavjee S, Kim H-R, Koh W-J, Lancaster J, Lange C, de Lange WCM, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MID, Ponce-de-León A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, VAn der Walt M, van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim J-J, on behalf of the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS Medicine 2012;9:1-9. [Ref.ID 92933]
7.
Menzies D, Long R, Trajman A, Dion MJ, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection. A randomized trial. Ann Intern Med 2008;149:689-97. [Ref.ID 84607]
Seleccionar todas
 
 1 a 7 de 7